乙酰半胱氨酸联合噻托嗅铵吸入治疗急性加重期COPD疗效及对氧化应激因子和炎症因子的影响

doi:10.3969/j.issn.1006-6233.2021.08.035

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1219 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究乙酰半胱氨酸联合噻托嗅铵吸入治疗急性加重期慢性阻塞性肺疾病(COPD)疗效及对氧化应激因子和炎症因子的影响。方法: 纳入2019年1月至2021年1月期间163例COPD急性加重期患者作为研究对象,根据非随机临床同期对照研究分为两组,其中观察组92例采用乙酰半胱氨酸吸入剂联合噻托嗅铵吸入剂治疗,对照组71例采用噻托嗅铵吸入剂治疗。比较两组患者治疗2周后临床疗效,治疗前、治疗2周后肺功能[第1秒用力呼气容积(FEV1)、最大呼气峰流速值(PEF)、肺活量50%时的呼气流速(PEF50)、肺总容量(TLC)]、动脉血气指标[氧饱和度(SaO₂)、血氧张力(PaO₂)、二氧化碳分压(PaCO₂)、酸碱度(PH)]、血清氧化应激指标[丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)]及炎症因子[降钙素原(PCT)、超敏C反应蛋白(hs-CRP)]水平变化。结果: 治疗2周后,观察临床总有效率高于对照组(P<0.05);两组FEV1、PEF、PEF50、TLC均较治疗前提高,且观察组变化幅度大于对照组(P<0.05);两组SaO₂、PaO₂、PH均较治疗前提高,PaCO₂均较治疗前降低,且观察组变化幅度大于对照组(P<0.05);两组血清SOD水平均较治疗前提高,MDA、NO均较治疗前降低,且观察组变化幅度大于对照组(P<0.05);两组血清hs-CRP、PCT水平均较治疗前降低,且观察组变化幅度大于对照组(P<0.05)。结论: 乙酰半胱氨酸联合噻托嗅铵吸入治疗急性加重期COPD可提高疗效,有效抗氧化、抑制炎症反应。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邝向东
	蔡林再
	谢景臣
	秦玉春

关键词 ：慢性阻塞性肺疾病, 乙酰半胱氨酸, 噻托嗅铵, 急性加重期, 氧化应激, 炎症反应

Abstract：Objective: To explore the effect of acetylcysteine inhalation combined with tiotropium inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) and its influence on oxidative stress factors and inflammatory factors. Methods: A total of 163 patients with acute exacerbation of COPD between January 2019 and January 2021 were enrolled as the research subjects, and they were divided into two groups based on nonrandomized clinical concurrent control study. Among them, 92 cases in the observation group were administered acetylcysteine inhalation combined with tiotropium inhalation, and 71 cases in the control group were treated with tiotropium inhalation. The clinical efficacy after 2 weeks’ treatment, as well as lung function [forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), expiratory flow rate at 50% vital capacity (PEF50), total lung capacity (TLC)], arterial blood gas indexes [oxygen saturation (SaO₂), partial pressure of blood oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂), PH], serum oxidative stress indicators [malondialdehyde (MDA),superoxide dismutase (SOD), nitric oxide (NO)] and inflammatory factors [procalcitonin (PCT),hypersensitive C-reactive protein (hs-CRP)] before treatment and after 2 weeks’ treatment were compared between the two groups. Results: After 2 weeks’ treatment, the total clinical effective rate of observation group was higher than that of control group (P<0.05). The FEV1, PEF, PEF50 and TLC of the two groups were improved compared with those before treatment, and the changes of observation group were greater than those of control group (P<0.05). The SaO₂, PaO₂ and PH of the two groups were increased while the PaCO₂ was decreased compared to before treatment, and the changes were greater in observation group compared to control group (P<0.05). The level of serum SOD of the two groups was higher than that before treatment while the levels of MDA and NO were lower than those before treatment, and the changes of observation group were greater compared with those of control group (P<0.05). The levels of serum hs-CRP and PCT in the two groups were lower than those before treatment, and the changes were greater in observation group than those in control group (P<0.05). Conclusion: Acetylcysteine inhalation combined with tiotropium inhalation in the treatment of acute exacerbation of COPD can enhance the efficacy, with anti-inflammatory and antioxidant effects.

Key words： Chronic obstructive pulmonary disease Acetylcysteine inhalation Tiotropium inhalation Acute exacerbation Oxidative stress Inflammatory response

基金资助:海南省卫生健康行业科研项目,(编号:20A200304)

引用本文:

邝向东, 蔡林再, 谢景臣, 秦玉春. 乙酰半胱氨酸联合噻托嗅铵吸入治疗急性加重期COPD疗效及对氧化应激因子和炎症因子的影响[J]. 河北医学, 2021, 27(8): 1399-1405.
KUANG Xiangdong, CAI linzai, XIE Jingchen, et al. Efficacy of Acetylcysteine Inhalation Combined with Tiotropium Inhalation in the Treatment of Acute Exacerbation of COPD and Its Influence on Oxidative Stress Factors and Inflammatory Factors. HeBei Med, 2021, 27(8): 1399-1405.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.08.035 或 http://www.hbyxzzs.cn/CN/Y2021/V27/I8/1399

[1] 武琰娇,张娜娜,柏少锋.异丙托溴铵联合乙酰半胱氨酸对慢性阻塞性肺疾病患者血浆与诱导痰巨噬细胞刺激蛋白表达及肺功能影响[J].临床军医杂志,2019,47(3):67~69.
[2] 刘虎,雷佳慧,赵丽敏.N-乙酰半胱氨酸泡腾片辅助治疗急性加重期哮喘-慢性阻塞性肺疾病重叠的临床疗效观察[J].中国医师进修杂志,2019,42(4):296~300.
[3] 胡姗姗,田凡清,杨贵丽,等.布地奈德福莫特罗粉吸入剂联合噻托溴铵喷雾剂对COPD急性加重期患者肺功能及血清MMP-9,TIMP-1水平的影响[J].中国地方病防治杂志,2019,34(4):94~96.
[4] 文春芳.慢性阻塞性肺疾病临床诊治分析[J].中国保健营养,2020,30(6):91.
[5] 盛利,陆映昭,陈光泽.CRP与PCT联合检测在慢性阻塞性肺疾病急性加重期老年患者诊治中的作用[J].慢性病学杂志,2019,20(3):64~66.
[6] 郝文东,王国芳,张彩莲,等.N-乙酰半胱氨酸联合双水平气道正压通气治疗AE-COPD合并Ⅱ型呼吸衰竭的疗效及作用机制研究[J].现代中西医结合杂志,2018,27(7):724~727.
[7] 彭科营.沙美特罗替卡松联合噻托溴铵治疗COPD并发重度支气管哮喘的临床效果观察[J].中南医学科学杂志,2017,45(6):544~547.
[8] Makhija R ,Divyaveer S .Angiography with sodium bicarbonate and acetylcysteine[J].New England Journal of Medicine,2018,378(18):1748.
[9] 樊聪慧,赵庆忠,张黔,等.N-乙酰半胱氨酸联合维生素E对COPD急性加重期患者炎性指标,血气水平及呼吸困难量表评分的影响[J].临床和实验医学杂志,2020,19(24):58~61.
[10] 张林,范晓东,许红阳.乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期患者肺功能和血清炎性因子及抗氧化指标水平的影响[J].中国医药,2018,13(7):1016~1020.
[11] 谢梦莹.N-乙酰半胱氨酸治疗老年COPD患者的疗效及对免疫功能和祛痰效果的影响[J].河北医药,2018,40(24):3781~3783,3787.
[12] 徐升,张念志,徐经世.益气化痰祛瘀方对慢性阻塞性肺病急性加重期血清同型半胱氨酸,组织纤溶酶原激活物,纤溶酶原激活物抑制物-1水平的影响[J].安徽医药,2020,24(7):175~178.
[13] 姜鑫鑫,钱晓凌,张维维,等.清宣止咳颗粒联合乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床效果[J].中国医药导报,2019,16(9):123~126.